NEW YORK, NY / ACCESSWIRE / December 7, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

UIS Shareholders Click Here: https://www.zlk.com/pslra-1/unisys-corporation-lawsuit-submission-form?prid=34384&wire=1
VERU Shareholders Click Here: https://www.zlk.com/pslra-1/veru-lawsuit-loss-submission-form?prid=34384&wire=1
NEO Shareholders Click Here: https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=34384&wire=1

* ADDITIONAL INFORMATION BELOW *

Unisys Corporation (NYSE:UIS)

UIS Lawsuit on behalf of: investors who purchased August 3, 2022 - November 7, 2022
Lead Plaintiff Deadline: January 10, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/unisys-corporation-lawsuit-submission-form?prid=34384&wire=1

According to the filed complaint, during the class period, Unisys Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's 2022 financial guidance was significantly overstated; (ii) accordingly, once the truth was revealed, it was likely that the Company would be required to negatively revise its 2022 financial guidance; (iii) in addition to the foregoing, material weaknesses existed in the Company's internal control over financial reporting; and (iv) as a result of all of the foregoing, the Company's public statements were materially false and misleading at all relevant times.

Veru Inc. (NASDAQ:VERU)

This lawsuit is on behalf of all investors who purchased or otherwise acquired Veru Inc. common stock between May 11, 2022 and November 9, 2022, inclusive.
Lead Plaintiff Deadline: February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/veru-lawsuit-loss-submission-form?prid=34384&wire=1

According to the filed complaint, 1) the Company had withheld material adverse facts about the data from the sabizabulin Phase 3 trial and the Company's interactions with the United States Food and Drug Administration; 2) defendants misled Veru's shareholders to believe that the data from the sabizabulin Phase 3 trial was sufficient to support Emergency Use Authorization ('EUA') and even the submission of a New Drug Application without any further studies; and 3) the Company's filings concealed the true risks faced by Veru in gaining approval for its EUA request.

NeoGenomics, Inc. (NASDAQ:NEO)

NEO Lawsuit on behalf of: investors who purchased February 27, 2020 - April 26, 2022
Lead Plaintiff Deadline: February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=34384&wire=1

According to the filed complaint, during the class period, NeoGenomics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants represented to investors that it had a 'comprehensive menu' of cancer tests with 'every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing,' which positioned the Company as a 'one-stop-shop' for pathologists and gave NeoGenomics 'a competitive advantage' as a 'go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer' and (2) defendants represented that NeoGenomics could 'leverage' the supposedly 'fixed cost' structure of its business to improve profitability as revenue increased and touted the Company's 'robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business.'

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP